middle.news
How Lumos’ US$317M Deal Could Revolutionize Rapid Respiratory Testing
10:31am on Wednesday 16th of July, 2025 AEST
•
Healthcare
Read Story
How Lumos’ US$317M Deal Could Revolutionize Rapid Respiratory Testing
10:31am on Wednesday 16th of July, 2025 AEST
Key Points
Six-year exclusive US distribution deal valued up to US$317 million
Upfront payments of US$2 million including exclusivity fee and pre-paid orders
Milestone payments linked to FDA CLIA waiver application and approval
PHASE Scientific to co-brand and distribute FebriDx® across US healthcare settings
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE